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The objective of this study was to undertake a comprehensive long-term biocompatibility and imaging
assessment of a new intrinsically radiopaque bead (LC Bead LUMI™) for use in transarterial embolization.
The sterilized device and its extracts were subjected to the raft of ISO10993 biocompatibility tests that
demonstrated safety with respect to cytotoxicity, mutagenicity, blood contact, irritation, sensitization,
systemic toxicity and tissue reaction. Intra-arterial administration was performed in a swine model of
hepatic arterial embolization in which 0.22e1 mL of sedimented bead volume was administered to the
targeted lobe(s) of the liver. The beads could be visualized during the embolization procedure with
ﬂuoroscopy, DSA and single X-ray snapshot imaging modalities. CT imaging was performed before and
1 h after embolization and then again at 7, 14, 30 and 90 days. LC Bead LUMI™ could be clearly visualized
in the hepatic arteries with or without administration of IV contrast and appeared more dense than
soluble contrast agent. The CT density of the beads did not deteriorate during the 90 day evaluation
period. The beads embolized predictably and effectively, resulting in areas devoid of contrast enhance-
ment on CT imaging suggesting ischaemia-induced necrosis nearby the sites of occlusion. Instances of off
target embolization were easily detected on imaging and conﬁrmed pathologically. Histopathology
revealed a classic foreign body response at 14 days, which resolved over time leading to ﬁbrosis and
eventual integration of the beads into the tissue, demonstrating excellent long-term tissue compatibility.
© 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Embolotherapy is a procedure for introducing a variety of agents
into the circulation in order to occlude blood vessels for therapeutic
intent, for instance to prevent bleeding, to arrest ﬂow through
abnormal connections such as arteriovenous malformations
(AVMs) or to devitalise a structure, organ or tumorous mass by
inducing ischemic necrosis. Embolic agents come in many different
forms including microparticles, pellets, glues or metallic coils [1,2].
These embolics are administered to targeted tissues through aE, transarterial embolization;
ngiography; IV, intravenous;
wis).
er Ltd. This is an open access articcatheter inserted andmanoeuvred through the vasculature into the
desired location. One common application of this technique is the
use of microparticles, most usually microspheres/beads to treat
tumors in the liver where the intention is to physically occlude the
vessels feeding the tumour in order to induce localised ischemic
necrosis of the malignant mass. However, perfect tumour targeting
of microparticles is not possible and embolization of normal adja-
cent healthy liver parenchyma is inevitable. The embolization of
healthy liver parenchyma can induce signiﬁcant local tissue
changes, including elevated serum liver enzymes and tissue dam-
age, but these side-effects typically resolve over time [3]. However,
there should be no chronic material-related inﬂammatory reaction
or clinical sequelae. The microparticles themselves may disappear
over time if bioresorbable, or if non-degradable, should be sufﬁ-
ciently bioinert and well-tolerated in tissue where they reside.
Embolotherpy with microparticles is conducted under X-rayle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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contrast agent, a radiodensematerial, is used to create a roadmap of
the network of blood vessels to be embolized. Some embolic de-
vices such as coils are inherently radiopaquewhich enables them to
be easily located during and post procedure. Liquid embolics such
as Glue or Onyx® are often mixed with radiodense materials (such
as Lipiodol® oil or tantalum powder) prior to use in order to impart
radiopacity [4,5]. Microparticles are usually composed of synthetic
and natural polymers that are radiolucent and therefore cannot be
directly seen during delivery which requires the addition of iodine-
based liquid contrast agent tomonitor their delivery. However, only
the degree of blood ﬂow cessation indicates when sufﬁcient
embolic agent has been delivered to achieve the desired ﬂow-based
embolization end-point. It has been demonstrated using embolic
bead devices that there is a degree of trapped residual soluble
contrast agent retention at the site of embolization that dissipates
over the next several hours post-procedure [6,7]. CT imagingwithin
a 6 h time frame post-delivery therefore, provides contrast reten-
tion as a surrogate marker of bead location and some degree of
comfort that the correct blood vessels have been embolized. The
exact bead location, however, remains unknown.
The concept of intrinsically radiopaque embolic beads has been
explored for many years [8] and multiple experimental studies are
available in the literature. In some cases the beads have been made
radiodense by the incorporation of metallic components such as
tantalum [9] or barium [9,10]. This can have signiﬁcant effect on the
handling and administration of the beads as the increased density
induces rapid sedimentation [11]. There is also concern for the
long-term fate of the entrapped contrast material and the potential
for leaching into the surrounding tissue over time. The incorpora-
tion of iodine-containing species into polymers has therefore been
a more widely studied approach, resulting in materials useful as
bulking agents [12], in bone cements [13,14], for nucleus pulposus
replacement [15,16] and as microparticle emboli [17,18]. The radi-
opacity can be introduced bymeans of an iodine-bearing monomer
at the polymerization stage [17e19] or by chemical attachment of
an iodinated species with reactive functionality to preformed
polymer microspheres [20]. Compounds based upon iodinated
benzyl groups are convenient starting materials for either of these
approaches as they provide for synthetic ﬂexibility and enable high
iodine content per unit mass. It is for these reasons that such
compounds are the basis for most of the commercially-available
soluble contrast media (Fig. 1 (1)). Radiopaque beads have been
prepared based upon incorporation of 2,3,5 triiodobenzyl moieties
(Fig. 1, (3 & 5)) [17], but whilst they possessed high unit iodine
content in the 25e30 wt% region, this somewhat compromised the
hydrophilicity and softness attributes that are desirable for the
handling and microcatheter delivery of embolization beads. Horak
et al. tried to address this problem with the synthesis of 3-(meth-
acryloylamido-acetamido)-2,4,6-triiodobenzoic acid (MABA, Fig. 1
(4)) and its subsequent copolymerization with HEMA in the pres-
ence of additives to induce porosity to the microspheres [21]. They
found it necessary to incorporate at least 27 wt% iodine for
adequate radiopacity but they experienced issues with irregular
particle formation and agglomeration during the polymerization.
Others have attempted to increase the hydrophilicity of the system
by utilising the mono-iodinated 2-[4-iodobenzoyl]-oxo-ethyl-
methacrylate monomer (4IEMA, Fig. 1, (2)) copolymerised with
hydrophilic comonomers such as hydroxyethyl methacrylate
(HEMA) or 1-vinyl-2-pyrrolidinone (NVP) [19]. Whilst this did
enable the synthesis of some microsphere formulations that were
water-swellable in nature, only those with low water content and
iodine contents of ~20 wt% were sufﬁciently radiopaque to be
useful in practice.
While it has been difﬁcult to establish a balance between theappropriate physicochemical properties (e.g., water content, den-
sity, sphericity, dispersibility) and useful levels of radiopacity, it has
been demonstrated that the materials based on the triiodinated
chemistry display good biocompatibility [23]. In vitro cell-based
analyses show no indications of cytotoxicity or effect on cell pro-
liferation, while in vivo implantation studies show they are well-
tolerated with no signs of adverse tissue reactions. We have
therefore recently reported on efforts to modify LC Bead®, well-
characterized polyvinylalcohol-based hydrogel beads for emboli-
zation of hypervascular tumors and AVMs. Approaches were
developed to activate the bead chemistry towards triiodinated
species (Fig. 1, (5)) to render them radiopaque whist maintaining
their hydrogel nature [20]. We have since optimized this chemistry
and have a process for manufacture of intrinsically radiopaque
beads (RO Beads) that have water contents in the region of 60e70%
with iodine contents in the range 189e258 mg/mL true bead vol-
ume (133e177 mg Iodine/mL sedimented beads, equivalent to
>60 wt% iodine on a dry mass basis) [22]. This provides for an
excellent degree of radiopacity coupled with the beneﬁts of a
hydrogel performance (Fig. 1, (scheme 6)). The additional visual
information provided by these beads may provide tools for stan-
dardization and reproducibility of end points and treatment effects
in addition to offering better conspicuity to determine target and
non-target embolization [22,24]. Furthermore, the durable imaging
appearance of the beads may also aid in the guidance and evalua-
tion of the embolization procedure. Intra-procedural identiﬁcation
of tissue at risk for under-dosing or under-treatment can better
inform the physician of options to immediately target this tissue
with additional therapies rather than waiting for the outcome of
follow-up scans [25]. In this study we present the outcome of the
biocompatibility testing of the optimized product, LC Bead LUMI™,
and investigate the long-term effects up to 90 days post emboli-
zation in a swine liver. We also concurrently examine the bead
location with X-ray ﬂuoroscopy and computed tomography (CT) as
well as the associated tissue changes resulting as a consequence of
their embolization.
2. Materials and methods
2.1. Materials
LC Bead LUMI™ used in this study was prepared and charac-
terized as described previously [22]. Brieﬂy, sulfonate-modiﬁed
acrylamido-polyvinylalcohol beads were made using a reverse
suspension polymerization process [26]. Triiodobenzyl groups
were coupled to the PVA chains of the preformed beads using a
proprietary process (scheme 6) to yield beads that were sieved into
different size fractions, dispensed into vials and steam sterilized.
The 70e150 mm size range of RO Beads was selected for the
biocompatibility and embolization studies as these provide a high
challenge given the large number of beads and high surface area for
a given volume. Visipaque™ 320 was used to make the bead sus-
pension. Each vial of beads (2 mL volume was mixed with 18 mL of
contrast agent taking care to eliminate any air bubbles from the
mixture.
2.2. ISO10993 biocompatibility studies
The biological evaluation of the RO Beads was based upon the
principles of ISO 10993-1: Biological evaluation of medical devices-
Part 1: Evaluation and testing within a risk management process
(ISO 10993-1: 2009). The biological evaluation took into account
the anticipated nature and duration of contact with RO Bead, which
is a permanent implanted device in contact with blood. All
biocompatibility testing studies (in vitro and in vivo) were
Fig. 1. The 2,4,6 triiodinated benzyl nucleus used in commercial contrast media (1); Examples of Iodinated vinylic monomers used in microsphere synthesis (2e4); Various 2,3,5
triiodinated compounds used to couple to polymers (5); and the schematic process for LC Bead LUMI™ synthesis [22](6).
Table 1
RO Bead imaging study design.
Time point Pilot study (6 mL RO beads) Main study (10 mL RO beads)
Animal# 1 2 3 4 5 6 7 8 9 10
Predose X X X X X X X X X X
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current Good laboratory Practice (GLP) regulations. In vivo studies
conformed to NAMSA Standard Operating Procedures that are
based on the “Guide for the Care and Use of Laboratory Animals,
National Academy Press, Washington, D.C., 2011.”1 h
postdose
X X X X X X X X X X
24 h
postdose
e X X e e e e e e e
Day 7 X e e X X X X X X X
Day 14 Xy Xy Xy Xy e e e e e e
Day 30 e e e e Xy Xy X Xy X X
Day 90 e e e e e e Xy e Xy
X ¼ Imaging performed; e ¼ No imaging performed; y ¼ Scheduled sacriﬁce day.2.3. Imaging evaluations in swine liver embolization safety model
2.3.1. Study design
The use of a control group is uncommon in this type of safety
assessment and not straight forward where both biocompatibility
and imaging aspects are under investigation. The non-radiopaque
equivalent of LC Bead LUMI™ is LC Bead™, which has itself been
tested in large animal safety studies and hence the biocompatibility
and tissue reaction to the bland embolization using this device is
known and reported [3]. From an imaging perspective, the useful-
ness of RO Beads regarding intra-procedural visibility has been
demonstrated already using control non-RO and RO Beads without
contrast in two recently published articles [22,24]. No control
group was therefore selected for comparison in this study.
This evaluation was performed in a swine liver embolization
safetymodel [3,27] at MPI Research Inc. (Mattawan, Michigan, USA)
using total of ten male experimentally naïve domestic Yorkshire
crossbred swine (farm pigs). The study was split into two phases: a
shorter pilot study (n ¼ 4 animals) in which a maximum volume of
RO Beads permitted delivery was ﬁxed at  6 mL and sacriﬁce was
scheduled for 14 days; and a longer term main study (n ¼ 6 ani-
mals) in which the volume of RO Beads permitted delivery was
raised to 10mL and sacriﬁcewas scheduled at 32 days (n¼ 3) and
91 days (n ¼ 3). The purpose of the pilot study was to determine a
volume of liver tissue embolized by a given volume of beads, whilst
avoiding off-target embolization in adjacent organs such as the
stomach, small bowel, pancreas and spleen before proceeding to
the longer term study. Imaging was performed at multiple time
points across both studies (Table 1) involving X-ray ﬂuoroscopy,
digital subtraction angiography (DSA), single shot X-ray and CT
with and without IV contrast injection. MPI Research Inc. Standard
Operating Procedures conditions conformed to USDA AnimalWelfare Act and “Guide for the Care and Use of Laboratory Ani-
mals”, Institute of Laboratory Animal Resources, National Academy
Press, Washington, D.C., 2011.
2.3.2. Hepatic embolization and X-ray imaging
Vascular access was obtained through femoral artery cut-down
and a sheath was placed for stable access. Through this sheath, a
combination of a guiding catheter, a 2.7 Frenchmicrocatheter and a
microguidewire was used to select the target hepatic lobe arteries.
A consistent angiography and embolization protocol was used
during the study. Under ﬂuoroscopic guidance, a guiding catheter
was placed at the entrance to the coeliac artery and an angiogram
was performed to visualize the branches of the coeliac artery. A
microwire and microcatheter combination was then used to select
the common hepatic artery, and lobar hepatic arteries supplying
approximately 50% of the total liver volume. This lobar selection
favored the left lateral or left median liver lobe whenever
anatomically feasible (to avoid embolization of the cystic artery). In
general, a larger artery size with no extrahepatic branches was
preferred and care was taken to avoid any vascular spasm or injury
during this step. A pre-embolization angiogram was performed to
conﬁrm the catheter tip position, deﬁne hepatic artery anatomy
and blood ﬂow, and visualize the liver volume to be embolized.
With the catheter in position and an appropriate target location
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ﬂuoroscopic guidance taking care to minimize reﬂux and avoid any
extra-hepatic non target embolization. A post-embolization
angiogram was also obtained. The fraction of liver area embolized
was estimated from the post embolization angiography and DSA
images. This was correlated and conﬁrmed on the post emboliza-
tion CT images, which provided a good approximation of the total
volume of liver embolized.
LC Bead LUMI™was prepared as a 1:10 dilution using iodinated
contrast medium (Visipaque™ 320) and delivered through the
microcatheter under continuous X-ray ﬂuoroscopic guidance. All
angiography and embolization procedures were performed using
the GE OEC 9000 elite or GE OEC 9800 C-arm units with the stan-
dard GE cardiac software package allowing cine loops at 30 frames
per second (fps) as well as digital subtraction angiography (DSA).
These C-arms allow for some automatic adjustments but basic
ﬂuoroscopy parameters used were peak kilovoltage (kVp) range of
85e95 and current range of 30e150 milliamperes (mA) and dose
range between 3.5 and 6.5 mGym2. Fluoroscopy and digital sub-
traction angiography (DSA) images were obtained before and after
embolization to document changes in arterial ﬂow and to visualize
the location of the beads in the embolized target. The embolization
was performed to clinically relevant angiographic endpoint of ﬁll in
Ref. [28] and care was taken to minimize off target embolization.
Review and comparison of pre- and post-embolization ﬂuoroscopy
and DSA images demonstrated the embolized target lobe(s), asso-
ciated changes in blood ﬂow, and location of RO Beads in each
animal. Single shot X-ray images were also obtained with tempo-
rary suspension of respiration (to improve image quality) approx-
imately 5 min after completion of embolization to also allow for
“wash out” of residual liquid contrast and better visualize the RO
Beads.
2.3.3. CT imaging and analysis
All CT scans were performed using a GE Lightspeed 16 CT
scanner and performed with helical acquisition using the following
parameters: thickness 1.25 mm, interval 1.25, kV 120, and mA
220e350. Multiplanar reformation in sagittal and coronal planes
was also performed. Abdominal CT scans without administration of
IV contrast were obtained before and 1 h (±30 min) after emboli-
zation with RO Beads. Additional CT scans with and without
administration of IV contrast (non-ionic, iso-osmolar IV contrast
agent such as Omnipaque™ or Visipaque™ (GE Healthcare)) were
obtained at 1, 7, 14, 30 and 90 days following embolization ac-
cording to the imaging schedule in Table 1. The contrast-enhanced
CT images in this study were routinely acquired in both portal-
venous and arterial phase (along with non-contrast enhanced CT
images). To the experienced user, close inspection of arterial phase
CT images does show subtle differences in appearance of arteries
containing RO Beads compared to those without beads, but this
may not be clinically relevant compared to the non-contrast and
portal-venous phase CT images. The non-contrast phase clearly
shows the location and distribution of the beads and the portal
venous phase shows parenchymal changes and venous structures
in addition to the bead-ﬁlled arteries. CT Images were reviewed in
axial, coronal and sagittal planes as well as in reconstructed
maximum intensity projection (MIP) images, by an Interventional
Radiologist with over 10 years experience in clinical practice and
highly familiar with preclinical evaluation in the porcine liver
embolization model. The MIP images display bone and other
radiodense structures such as IV contrast and RO bead-ﬁlled vessels
preferentially with other lower-attenuating structures being less
well visualized. The CT scans were reviewed for the following: i)
visibility of RO Beads, ii) location RO Beads within the liver, iii)
approximate area/volume of liver embolized, iv) extrahepatic offtarget embolization in adjacent organs including the stomach,
duodenum, spleen, pancreas and lungs, v) and other imaging
ﬁndings which could be related to hepatic embolization and asso-
ciated ischaemia.
2.4. Clinical pathology
Clinical pathology evaluations were conducted on all animals
before and after embolization on days 2, 7, 14, 21, 32, 61, and 91, as
applicable. The animals had access to drinking water but were
fasted overnight prior to each scheduled sample collection. Blood
samples (approximately 4.8e5.8 mL) were collected from the ju-
gular vein. The samples were collected into the appropriate tubes
for evaluation of haematology, clinical chemistry and coagulation
parameters. On occasion, blood samples were redrawn from ani-
mals if the initial samples had clotted. Urine samples were collected
using steel pans placed under the cages for at least 16 h.
2.5. Pathological evaluation in swine liver embolization model
Histopathology was conducted on tissues harvested post sacri-
ﬁce on the scheduled day (Table 1). Necropsy examinations were
performed under procedures approved by a veterinary pathologist
on all animals.
2.5.1. Macroscopic analysis
The animals were euthanized by sedationwith an intramuscular
injection of Telazol, followed by an intravenous overdose of sodium
pentobarbital solution and exsanguination by transection of the
femoral vessels. The animals were examined carefully for external
abnormalities including palpable masses. The skin was reﬂected
from a ventral midline incision and any subcutaneous masses were
identiﬁed and correlated with antemortem ﬁndings. The abdom-
inal, thoracic, and cranial cavities were examined for abnormalities.
The organs were removed, examined, and, where required, placed
in ﬁxative. Special attention was paid to the liver for abnormalities,
as well associated vasculature, surrounding tissue, gallbladder,
hepatic bile ducts, GI tract, lungs, heart, kidney, spleen, and brain.
All tissues were ﬁxed in neutral buffered formalin.
2.5.2. Microscopic analysis
Microscopic examination of ﬁxed hematoxylin and eosin-
stained parafﬁn sections was performed on sampled sections of
tissues. For some sections, Russell-Movat Pentachrome stain was
used in order to evaluate the presence of collagen and mucin. The
slides were examined by a board-certiﬁed veterinary pathologist.
Photomicrographs of representative lesions seen during the
microscopic examination, including those considered to be treat-
ment related, were taken.
3. Results and discussion
3.1. Biocompatibility testing
The biocompatibility tests conducted and their outcomes are
listed in Table 2.
All of the in vitro and in vivo biocompatibility tests performed
showed that neither the RO Bead nor any of its extract solutions
elicited any response that would be a concern when extrapolating
to the target liver cancer patient population.
3.2. Clinical observations
Over the course of the study, animals consumed their daily
allotment of food, gained weight in a normal manner and were
Table 2
Biocompatibility studies carried out on LC Bead LUMI™ and its extracts and their outcomes.
ISO standard Biocompatibility test Rationale Product testeda Pass/Fail
ISO10993 Part 3 Tests for
genotoxicity, carcinogenicity
and reproductive toxicity
Mouse lymphoma study To evaluate for mutagenic
potential
Extracts in DMSO and Serum-free
cell culture medium
Pass
Packing solution Pass
Mouse Peripheral blood
Micronucleus Study
To evaluate for the potential to
produce cytogenetic damage.
Extracts in saline and sesame oil Pass
Packing solution Pass
Bacterial Reverse Mutation
Study
Rapid screening for
determination of mutagenic
and potential carcinogenic
hazards
Extracts in DMSO and saline Pass
Packing solution Pass
ISO10993 Part 4 Selection of
tests for interactions with
blood
In vitro Hemolysis Study
(Modiﬁed ASTM-Direct Contact
Method)
To determine whether direct
contact with the test article
would cause in vitro red blood
cell hemolysis
RO Beads only Pass
Extract in CMF-PBS Pass
Packing solution Pass
ISO10993 Part 5 Tests for
in vitro cytotoxicity
Cytotoxicity Study using the ISO
Elution Method
To evaluate the cytotoxicity of a
test article extract using in vitro
mammalian cell culture test
Extract in single strength
Minimum Essential Medium
Pass
Packing solution Pass
ISO10993 Part 6 Tests for local
effects after implantation
ISO Muscle Implantation Study
in the Rabbit (2 weeks)
To evaluate the local tissue
response, 2 weeks after surgical
implantation
RO Beads only Pass
ISO Surgical Muscle
Implantation in the Rabbit (26
weeks)
To evaluate the local tissue
response, 26 weeks after
surgical implantation
RO Beads only Pass
Sub chronic Toxicity Study in
the Rat following Subcutaneous
Implantation (13 weeks)
To evaluate the potential
systemic toxicity following
subcutaneous implantation as
well as local irritation or
toxicity at the implant sites
RO Beads only Pass
ISO10993 Part 10 Tests for
irritation and skin
sensitization
ISO Sensitization Study in the
Guinea Pig
To identify the potential for
dermal sensitization
Extracts in saline and sesame oil Pass
ISO Acute Intracutaneous
Reactivity Study in the Rabbit
To evaluate the local dermal
irritant effects
Extracts in saline and sesame oil Pass
ISO10993 Part 11 Tests for
systemic toxicity
ISO Acute Systemic Toxicity
Study in the Mouse
To evaluate acute systemic
toxicity of a test article
following a single intravenous
or intraperitoneal injection
Extracts in saline (iv) and sesame oil (ip) Pass
Pyrogenicity, Rabbit Pyrogen
Study, Material Mediated
To evaluate for material
mediated pyrogenicity in the
rabbit
Extract in saline Pass
a The extraction conditions for most studies were performed at 70 C for 24 h.
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scheduled necropsy interval with the exception of animal number
10. Animal number 10 was found dead during the anaesthetic re-
covery period following the Day 32 CT imaging (approximately 1 h
after completion of CT scan). Off-target embolization of the phrenic
artery (Fig. 5, section 3.2) may have caused respiratory issues that
contributed to this animal's early expiration. Prior to the Day 32
imaging procedure, animal number 10was considered to be in good
health and was gaining weight normally.
3.2.1. Haematology
There were no RO Bead-related effects among haematology
parameters. All mean and individual values were considered within
expected ranges for biological and/or procedure-related variation.
At 1 h post-embolization there were mild transient decreases in
multiple haematology endpoints that were typical of a dilutional
effect caused by intravenous ﬂuid administration during the
embolization and imaging procedures. These ﬁndings included
mild decreases in red cell mass; and leukocyte, platelet, reticulo-
cyte, lymphocyte, monocyte, and basophils counts, relative to
pretest. By day 2 these ﬁndings had resolved and were generally
comparable to pretest for the remainder of the study.
3.2.2. Coagulation
Therewere no effects of RO Bead on coagulation times (i.e., APTT
and prothrombin time) at any collection interval, up to and
including the Day 91 collection. All individual and mean valueswere considered within an acceptable range for biologic, procedure
and assay-related variation. There was a mild and transient in-
crease in ﬁbrinogen at the Day 2 and 7 collection (þ17e46%),
relative to pretest values. Increases in ﬁbrinogen were consistent
with an inﬂammatory stimulus, as related to the anticipated liver
tissue injury/embolization; these effects had resolved by Day 14. .
All other mean and individual values were considered within ex-
pected ranges for biological and procedure-related variation.
3.2.3. Clinical chemistry
At the Day 2 collection, there was evidence of hepatocellular
injury, including mild increases in aspartate aminotransferase
(AST; þ192%), alanine aminotransferase (ALT; þ73%), sorbitol de-
hydrogenase (SDH;þ74%), and lactate dehydrogenase (LDH;þ84%),
relative to pretest values. Hepatocellular injury was attributed to
hepatic artery embolizationwith resulting hepatocellular ischemia.
These effects were mostly resolved (levels returned to baseline) by
the Day 7 collection. These transient elevations in liver enzymes
(transaminitis) are also routinely seen in clinical liver embolization
procedures.
3.3. Bead handling, delivery and imaging evaluation e ﬂuoroscopy,
DSA and single X-ray
RO Bead suspension (1:10 dilution of beads in iodinated contrast
medium) was found to be durable and easy to handle [22]. Agita-
tion of the delivery syringe every two to three minutes was
Fig. 2. Fluoroscopic, DSA and single X-ray images pre-embolization (a, c & e respectively) and post embolization (b, d & f respectively). Catheter tip position (yellow circle),
embolized left lobe (red circle), embolized arteries (yellow arrows) and RO Beads within target arteries (red arrows) are indicated. Fluoroscopic images (b) were taken during
contrast injection and showed the expected alterations in blood ﬂow due to embolization of the left lobe (diversion away from the embolized region) with soluble contrast proximal
to the catheter tip with retrograde ﬂow and reﬂux.
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delivery through the 2.7 Frenchmicrocatheter without any catheter
occlusion. Selective catheterization of the hepatic lobar branches
was successfully achieved in all animals (Fig. 2 yellow circle for
example) without complication. Embolizationwas performed using
RO Bead suspension volumes ranging from 2.2 to 10 mL (containing
0.22e1.0 mL of 70e150 mm bead volume) across the two phases ofthe study (Table 3).
Hepatic embolization with RO Beads was performed with
careful technique using slow injection and continuous ﬂuoroscopic
monitoring to devascularize target arteries (Fig. 2, (b,d) yellow ar-
rows for example) while avoiding reﬂux and off target extrahepatic
embolization. DSA was useful to show hepatic arteries containing
RO Beads that no longer ﬁlled with IV contrast, demonstrating
Fig. 3. Durable Visibility of RO Beads Observed with CT Scan. Top row shows images from CT scans obtained without soluble IV contrast (axial plane and soft tissue windows) that
clearly demonstrate RO Beads located in hepatic arteries after embolization of swine liver (yellow arrows). CT scans obtained at 7, 30 and 90 days following embolization show the
visibility and appearance of RO Beads persists and is unchanged over the 90 days. Bottom row shows images from CT scans obtained with soluble IV contrast (coronal plane and
bone windows; maximum intensity projection images) that clearly demonstrate that RO Beads seen in the hepatic arteries (yellow arrows) are more dense than, and clearly
differentiated from soluble IV contrast seen that is seen in the portal veins (red arrows).
Fig. 4. Tissue Changes Following Swine Liver Embolization. CT scans with soluble IV contrast obtained 30 days following embolization show dilation of bile ducts and small areas of
liver ischemia (red arrows) adjacent to hepatic arteries ﬁlled with RO Beads (yellow arrows) in two animals. These changes are consistent with ischemia resulting from hepatic
arterial embolization.
Fig. 5. Non Target Embolization detected with RO Beads. CT scan with soluble IV contrast obtained 30 days following embolization shows RO Beads ﬁlling the extrahepatic phrenic
artery (yellow arrows) indicating non target extrahepatic embolization which was not noted during embolization.
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indicative of the bead location in the arteries (Fig. 2d). Single shot
X-ray (red arrows, Fig. 2f) better visualize RO Beads. It is the casethat at very early time points during embolization (seconds to
minutes), before soluble contrast washes out, both beads and
contrast are present in the arteries and contribute to the observed
Table 3
Embolization procedure details (ND ¼ not determined).
Animal
number
Total volume (mL) of RO beads
delivered (1:10 dilution)
Extra-hepatic reﬂux noted
during embolization?
Extra-hepatic non-target
embolization noted on CT?
Approximate percentage
of liver embolized
1 2.2 No No ND
2 6.0 No No ND
3 5.5 No No ND
4 6.0 No No ND
5 5.5 No No 50
6 6.0 No No 50
7 6.5 No No 50
8 10 No No 50
9 7 No No 50
10 10 No Yes e phrenic artery 66
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largely the contribution of the beads. The CT scans obtained after
the procedure and repeated over time up to 90 days (see the
following sections) conﬁrm that the areas seen on the ﬂuoroscopy
and DSA images were in fact the location of the RO Beads.
3.4. Imaging evaluation e CT imaging analysis
Review of multi-planar CT data sets easily depicted the location
and three dimensional distribution of RO Beads within the hepatic
arteries of the embolized liver lobes, conﬁrming and further de-
tailing the ﬂuoroscopic ﬁndings. Although a systematic and quan-
titative review of visualized artery size was not undertaken, bead-
ﬁlled arteries measuring in the range of 1.5e2.5 mm or larger were
routinely seen on CT scans. Micro-CT is a higher resolution imaging
method that could be used on ex-vivo samples to more exquisitely
image bead distribution, but it was not performed in this study. We
have previously reported on the distributions of similar RO Beads in
swine liver using microCT [29]. The correlation between vessel
sizes ﬁlled with beads and imaged using conventional CT and
micro-CT is the subject of a follow-up investigation currently in
progress and will be reported separately in due course.
The RO Beads were easily visible on all post embolization CT
scans obtainedwithout administration of IV contrast andmoreover,
was also visible on CT scans obtained after administration of IV
contrast (venous phase imaging). This demonstrates that RO Beads
are highly dense and can be visualized with CT even in the presence
of tissue contrast provided by IV contrast administration (Fig. 3). CT
scans obtained over time demonstrate the durable visibility and
imaging appearance of RO Beads. Axial plane soft tissue window CT
images obtained without soluble contrast administration from a
representative animal are shown prior to and then at 7, 30 and 90
days following embolization with RO Beads. These images clearly
demonstrate beads located in the hepatic arteries of the embolized
swine liver. Clearly, the bright lines of beads are only observed in
the post embolization scans and remain visible with no obvious
deterioration in image density over the 90 day period of the study.
The appearance of the RO Beads in the embolized liver, including
their unchanged density and distribution over the 90 day time
period are better appreciated on the coronal plane bone window
thick slab MIP CT images obtained with soluble contrast adminis-
tration. These images show bead ﬁlled arteries in relation to the
soluble contrast ﬁlled portal veins.
Close examination of CT scans shows no evidence of off target
embolization in adjacent organs including the stomach, duodenum,
spleen, pancreas and lungs. In 4 of 10 animals, focal areas of
decreased contrast enhancement on venous phase CT images
consistent with reduced perfusion and hepatic ischemia in the
targeted liver lobes were seen on CT scans obtained 7e90 days after
embolization. These expected effects of embolization are shown inFig. 4. These tissue changes were often closely co-located with the
presence arteries densely ﬁlled with beads. The overall size of these
areas of reduced enhancement often decreased at days 30 and 90
compared to day 7, suggesting some interval recovery. These areas
also corresponded to those seen in the pathological analysis
composed of wide areas of hepatic necrosis (section 3.4). The 14, 30
and 90 day CT scans also show some dilated bile ducts in the
embolized liver, most of which are in a peripheral location (Fig. 4).
These are best seen on scans with IV contrast and are often located
adjacent to embolized arteries; most likely related to bile duct
ischemia caused by embolization. This also correlates well with the
observed presence of bile duct hyperplasia seen in some of the
pathological analysis of these samples (section 3.4). This is an ex-
pected ﬁnding as the blood supply to the bile ducts is solely derived
from branches of the hepatic artery (which has been embolized).
The surrounding hepatocytes, on the other hand, derive their blood
supply from both the hepatic artery and portal vein and, therefore
are relatively protected from arterial embolization.
Although no off-target embolization to organs adjacent to the
liver was seen in any of the animals, one animal (animal 10) failed
to reach its scheduled sacriﬁce time point at 91 days since it did not
recover from the anesthesia following the 30 day CT scan. Embo-
lization of the phrenic artery (the blood supply to the diaphragm)
was clearly identiﬁed by the presence of RO Beads in this artery on
the post-embolization CT scans (discovered after necropsy and not
speciﬁcally examined during the pathology evaluation, Fig. 5). It is
possible that the hepatic ischemia/necrosis in the left lobe (possibly
a result of the greater volume of liver embolized (66% compared to
50% for the other animals, Table 3) in this animal) and the non-
target embolization of the phrenic artery both contributed to dif-
ﬁculty in recovery from anesthesia and early expiration of this
animal.
3.5. Pathological evaluation
3.5.1. Macroscopic observations
Macroscopic observations in the embolized portion of the liver
included the appearance of multiple focal tan regions. These
macroscopic observations were associated with microscopic ﬁnd-
ings of hepatic necrosis, ﬁbrosis, and leukocyte inﬁltrates antici-
pated following embolization of liver arteries with microparticles.
In one animal (animal 1), abdominal cavity adhesions (omentum
adhered to the gallbladder and right median liver lobe) and
swollen/thickened gallbladder were associated with microscopic
ﬁndings of gallbladder necrosis, oedema, ﬁbrosis, and neutrophil
inﬁltrate due to injection of RO Beads. Review of the imaging
conﬁrmed that the artery supplying the gall bladder (cystic artery)
was included in the target region embolized in this animal.
Therefore, the macroscopic and histological changes observed in
the gall bladder were related to and expected from embolization of
Fig. 6. H&E stained sections of (a) RO Beads in the gallbladder of animal 1 (yellow arrows); (b) areas of focal coagulative necrosis and ﬁbrosis (yellow star) and the presence of
clusters of RO Beads (yellow arrows) in animal 3; (c) magniﬁed view of the left lateral lobe of animal 4 showing focal coagulative necrosis (yellow star) and ﬁbrosis (red star).
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brain, common bile duct, heart, kidneys, lung, pancreas, spleen,
duodenum, jejunum, ileum, and cecum of any of the animals.3.5.2. Microscopic observations e day 14
RO Beads were present within arteries of the treated liver lobe
from all treated animals as expected. In animal number 1 and 3, RO
Beads were present within blood vessels of the treated liver lobe
and gallbladder (Fig. 6 (a)). Lesions in the gallbladder wall of animal
3 were severe necrosis and oedema, moderate ﬁbrosis, and mild
neutrophilic inﬁltration, which was noted in the CT imaging anal-
ysis as abnormal gallbladder wall thickening. Focal coagulative
necrosis of several liver lobules and mild increased interlobular
ﬁbrosis were present in the treated liver lobes (Fig. 6 (b& c)). These
changes are consistent with hepatic ischemia resulting from
embolization and also consistent with the areas of decreased
enhancement on the CT scans (Fig. 6). In animal number 4 RO Beads
were present within blood vessels of treated (left median lobe) and
left lateral liver lobes. Focal coagulative necrosis of several liver
acini was present in the left lateral liver lobe. A zone of ﬁbrosis and
mixed leukocyte inﬁltrate (primarily neutrophils) was adjacent to
the necrotic area (Fig. 6 (c)).
RO Beads were often observed clustered together within the
larger arteries (Fig. 7). The beads appear as dark blue objects due to
the H&E staining and maintain a spherical morphology in the
vessels, surrounded in a matrix of granulation tissue. Often the
bead may appear misplaced out of the artery, or completely
missing, leaving a hole where it was originally embedded; this is an
artefact of the sectioning of the sample (Fig. 7 (b)). Enlarged bileFig. 7. H&E sections from animal 2, day 14: (a) RO Beads were present within arteries of the
around liver lobules. Thrombus was often present in small blood vessels (T); (b) RO Beads in
bile duct (B). The black arrow denotes an enlarged bile duct close to an embolized artery. Tducts are also visible, a hyperplasia associated with the ischemia
induced by the embolization of the artery which provides the bile
duct blood supply. This observation supports the presence of
dilated bile ducts noted on the CT imaging shown in Fig. 4.
3.5.3. Microscopic observations e day 32
Occlusion of medium sized arteries (typically 0.5e1 mm in
diameter) was noted in animals 6 and 10 (Fig. 8). Affected arteries
had lodged beads surrounded by mesenchymal/epithelial cells and
deposition of mucin and connective tissue resulting in complete
ﬁlling (occlusion) of the vessel lumen. The beads took on an
interesting pattern of staining from the Pentachrome stain used to
highlight the connective tissues, appearing like frogspawn with a
clear outer layer (Fig. 8(c&d)). The endothelium of affected vessels
was frequently absent and the beads were immediately adjacent to
the elastic membrane. Microvascular networks (neo-
vascularization) were present within the newly formed intravas-
cular connective tissue stroma in some sections. These tissue
observations are consistent with a the classic foreign body
response, with the arterial structure being remodelled with an
initial invasion of inﬂammatory cells with these subsequently
replaced by connective tissues with the beads being walled off by a
ﬁbrotic layer (Fig. 8(c&d)).
3.5.4. Microscopic observations e day 91
On Day 91, RO Beads were present in remnants of blood vessels
or what appeared to be hepatic parenchyma. In arteries, the lumens
were replaced bymature-appearing collagen/connective tissue that
occluded the vessel and encompassed the beads. Small arteries/treated liver lobe (yellow arrows). Minimally increased interlobular ﬁbrosis was present
side the hepatic artery branch located in a classic triad of artery (A), portal vein (V) and
hrombus is also present in a branch of the artery A.
Fig. 8. Stained sections of the liver, Day 32. H&E stain, animal 10: (a) Clusters of RO Beads are visible in a large artery, surrounded by an area of hepatocyte necrosis, ﬁbrosis and
inﬂammation encapsulating the necrosis (red star); (b) High magniﬁcation of the coagulative necrosis of hepatocytes-note the absence of cell in this tissue matrix. Pentachrome
stain, animal 6: (c) Cluster of beads in medium size artery stained using Russell-Movat Pentachrome stain revealing a collagen-rich layer surrounding the beads (yellow); (d) Higher
magniﬁcation of RO Beads within the lumen of a medium sized artery (Russell-Movat Pentachrome stain, Collagen: Yellow; Elastic Fibres: Black to Blue/Black; Mucin: Blue).
Fig. 9. H&E sections of liver, Day 91. (a) Lumen of an artery in the liver containing beads surrounded by mature collagen ﬁlling the space between beads. Clear spaces are presumed
to be sites of beads that were displaced during tissue processing. Small arteries/veins were present in the new intravascular connective tissue stroma (red arrow, neovascularization;
green arrow, mature collagen; yellow arrow, tunica muscularis of artery wall). (Hematoxylin-Eosin stain); (b) Beads within the parenchyma of the liver without evidence of a tissue
injury or inﬂammatory response. Classic triad of artery (A), vein (V) and bile duct (B). (Hematoxylin-Eosin stain).
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Individual beads were observed interspersed between hepatocytes.
The beads were frequently near blood vessels but were surrounded
by hepatocytes. There was no evidence of tissue injury or inﬂam-
matory response to the beads indicating that the material that the
beads are composed of is highly biocompatible in nature.
4. Conclusions
The objective of this study was to evaluate the safety, biocom-
patibility, imaging appearance and tissue effects of hepatic embo-
lization with a novel radiopaque bead (an embolic agent,70e150 mm in size), in a swine model. The results of this study
demonstrate that administration of up to 1 mL of sedimented LC
Bead LUMI™ via the hepatic artery produced no effect on food
consumption and the ability to gain body weight, electrocardio-
graphic endpoints and urinalysis parameters. Transient changes
were noted in haematology and coagulation values but these were
considered to be related to the embolization-associated ischaemia.
Embolization with RO Beads was also associated with minimal
transient increases in the activities of AST and ALT on Day 2, but
these had resolved by Day 7 as previously observed in this model
[3]. These ﬁndings are typical of clinical ischemic hepatocellular
injury and were anticipated as a result of acute hypoxia induced in
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LC Bead LUMI™ in this study is shown to be highly biocompatible,
having passed all standard ISO10993 biocompatibility tests. Histo-
pathological analysis of the device at 14, 30 and 90 days showed a
classic foreign body response with initial inﬂammation, ﬁbrosis and
tissue remodelling to yield complete integration of the device into
the tissue with no observed chronic inﬂammatory response. This
study also demonstrates that this device performs its intended pri-
mary function of being able to embolize arteries, leading to targeted
regions of ischemia and induction of focal areas of tissue necrosis
located adjacent to the beads. Features such as dilated bile ducts or
gallbladder embolization were expected as a consequence of the
embolization procedure, were noted in the histopathology and
correlated well with features observed during the CT imaging anal-
ysis. The lack of any loss of RO Bead image intensity over the 90 day
period and the completely benign response to the tissue surrounding
the beads suggests no loss of the triiodinated species over this time
frame in vivo, conﬁrming that the covalent attachment of the radi-
opaque moiety to the bead is stable in the body.
A useful aspect of this novel device is its inherent radiopacity,
allowing it to be visualized on X-ray angiography during the
embolization procedure, enabling the user to observe ﬁlling of
target arteries and also potentially off-target arteries if reﬂux occurs
or the catheter is misplaced [22,25]. It should be noted that it is
currently recommended that LC Bead LUMI™ is administered as a
suspension in pure iodinated liquid contrast medium in order to (i)
better suspend the beads and (ii) allow a sense of directionality and
ﬂow velocity when injecting very small aliquots of suspension. As
both the beads and contrast agent are radiopaque by virtue of the
presence of iodine in their structures, they cannot be distinguished
from one-another with ﬂuoroscopy as they leave and ﬂow away at
the microcatheter tip. Once trapped in the artery, beads become
more distinguishable as the liquid contrast medium washes away
(the majority in minutes but a small residual amount can be trap-
ped for some hours if the degree of embolization is high). As small
vessels well below 0.4 mm in diameter can be clearly seen under
single shot resolution [22] then the initiation of non-target embo-
lization may be observed early on and action taken to avoid addi-
tional off-target vessel occlusion. In some cases this early signal
may be sufﬁcient to avoid signiﬁcant damage but this will be highly
dependent upon the criticality of the non-target vessels embolized.
Indeed, in this study a contributory cause of the early expiration of
one of the animals was off-target embolization of the phrenic ar-
tery, which even though could be clearly seen on the 30 day CT
images, was not recognized at the time of the procedure.
In addition to X-ray, the RO Beads are also clearly visible on CT, a
ﬁnding shown on the 7, 14, 30 and 90 day CT scans obtained with or
without IV contrast administration as the beads are more radio-
dense than the IV contrast and appear brighter. The beads are best
seenwithout IV contrast, as they are easily visible in branches of the
hepatic arteries without the confounding inﬂuence of soluble
contrast in the tissue and the CT imaging appearance remains
consistent over the 90 day study period. This will allow the
physician to know the exact position of the beads on CT scans
performed shortly after embolization and on long-term follow-up
CT scans which along with MRI (magnetic resonance imaging) are
routinely used in clinical practice to follow progress of liver cancer
patients that have been treated with transarterial embolotherapy. It
is hoped that the ability to clearly identify the location of the beads
during and post-delivery will enable the interventional radiologist
performing embolotherapy to better identify areas of under-
treatment and be more wary of potential off-target occurrences.
LC Bead LUMI™ therefore represents a true step forward in the
improvement of minimally-invasive image-guided transarterial
embolization.Acknowledgements
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